Carrageenan

What this is

Food-grade carrageenan is often evaluated alongside processed Eucheuma seaweed, or E407a, but it is distinct from poligeenan, a lower-molecular-weight acid-degraded carrageenan not authorized as a food additive. U.S., Codex/JECFA, Canada, and EU systems generally permit food-grade carrageenan under conditions of use. EFSA’s 2018 re-evaluation found no genotoxicity or carcinogenicity concern, but kept a temporary group ADI and requested better data on molecular-weight distribution, potential degradation, impurities, infant uses, and gastrointestinal relevance. JECFA’s position evolved: after earlier infant-formula caution, later review concluded that use up to 1000 mg/L in infant formula or formula for special medical purposes was not of concern. A small 2024 human crossover trial found increased intestinal permeability and BMI-related inflammatory/metabolic signals, but no overall insulin-sensitivity difference and no exposure-related adverse events. Overall, this supports a Limited concern tier: not a broad-ban additive, but not a “no signal” ingredient either.

Safety Review

The critical endpoints experts review in safety assessments. This is not a prediction of harm.

Traditional toxicology is broadly reassuring: food-grade carrageenan is not absorbed intact, and EFSA did not find genotoxicity or carcinogenicity concern. The main unresolved issue is gastrointestinal relevance. A small human trial reported increased intestinal permeability and BMI-linked inflammatory/metabolic signals, while EFSA requested more infant-specific and molecular-weight data.